Company Profile
Shattuck Labs Stock Price, News & Analysis
- Ticker:
- STTK
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.16 USD (-2.85%)
Close
Last updated: August 6, 2026
373M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, STTK closed down 2.85% at $7.16. No new same-company headline was identified in the current news window.
Company overview
Immune-Mediated Diseases
Shattuck Labs develops antibodies for inflammatory and immune-mediated diseases. Its current strategy centers on blocking death receptor 3, a regulator of activated immune cells.
SL-325
SL-325 is a monoclonal antibody targeting DR3. The candidate has completed enrollment in a Phase 1 single- and multiple-ascending-dose study and is being prepared for Phase 2 development in Crohn's disease.
DR3 Platform
Shattuck is also exploring bispecific DR3-blocking antibodies and additional indications where excessive DR3 signaling may contribute to chronic inflammation.
Future catalysts
Comprehensive Phase 1 data for SL-325 in the second quarter of 2026.
Initiation of a Phase 2 study of SL-325 in Crohn's disease in the third quarter of 2026.
Recent news
- 01
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
Source: Shattuck Labs
- 02
Shattuck Labs, Inc. Announces Proposed Public Offering
Source: Shattuck Labs
- 03
- 04
Shattuck Labs Announces Phase 1 Results for SL-325
Source: Shattuck Labs
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Shattuck Labs (STTK)?
Shattuck Labs (STTK) most recently closed at 7.16 USD, a -2.85% move versus the previous session.
What is the market cap of Shattuck Labs (STTK)?
Shattuck Labs currently has a market capitalization of 373M USD on BioPharmSignal.
What does Shattuck Labs do?
Immune-Mediated Diseases Shattuck Labs develops antibodies for inflammatory and immune-mediated diseases. Its current strategy centers on blocking death receptor 3, a regulator of activated immune cells. SL-325 SL-325 is a monoclonal antibody targeting DR3. The candidate has completed enrollment in a Phase 1 single- and multiple-ascending-dose study and is...
On which exchange is STTK stock listed?
Shattuck Labs (STTK) is associated with NASDAQ, United States, Biopharma.
What is SL-325?
Comprehensive Phase 1 data for SL-325 in the second quarter of 2026.
Which conditions is Shattuck Labs targeting with SL-325?
Shattuck Labs is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does Shattuck Labs describe recent progress with SL-325?
Comprehensive Phase 1 data for SL-325 in the second quarter of 2026.
What is Immune-Mediated?
Immune-Mediated Diseases Shattuck Labs develops antibodies for inflammatory and immune-mediated diseases.